Naoual Harid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Naoual Harid has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Bruno Fautrel
Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, AP-HP; Sorbonne Université, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidemiologie (Cephepi) CIC-1422, Paris, France
2 shared publicationsEric Lespessailles
Rheumatology Department, Orléans Regional Hospital, Orléans, France
2 shared publicationsFlorence Tubach
Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, AP-HP; Sorbonne Université, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidemiologie (Cephepi) CIC-1422, Paris, France
2 shared publicationsPhilippe Bertin
Rheumatology Department, Limoges University Hospital, Limoges, France
2 shared publicationsPhilippe Goupille
Rheumatology Department, Tours University Hospital, Tours, France
2 shared publicationsRené-Marc Flipo
Rheumatology Department, Lille University Hospital, Lille, France
2 shared publications
Latest Publications
- 21 May 2021
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 39 (3) , 537-545
Real-life persistence of golimumab in patients with chronic inflammatory rheumatic diseases: results of the 2-year observational GO-PRACTICE study
Full Papers; Authors: R.-M. Flipo, F. Tubach, P. Goupille, E. Lespessailles, N. Harid, S. Sequeira, P. Bertin, B. Fautrel
- 21 May 2021
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 39 (3) , 537-545
Real-life persistence of golimumab in patients with chronic inflammatory rheumatic diseases: results of the 2-year observational GO-PRACTICE study
Full Papers; Authors: R.-M. Flipo, F. Tubach, P. Goupille, E. Lespessailles, N. Harid, S. Sequeira, P. Bertin, B. Fautrel
- 24 March 2021
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 40 (7) , 1352-1360
Real-life golimumab persitence in patients with axial spondyloarthritis: post-hoc results of the prospective observational cohort study, GO-PRACTICE
Full Papers; Authors: P. Goupille, P. Bertin, F. Tubach, E. Lespessailles, N. Harid, S. Sequeira, J.-M. Fayette, B. Fautrel, R.-M. Flipo
- 24 March 2021
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 40 (7) , 1352-1360
Real-life golimumab persitence in patients with axial spondyloarthritis: post-hoc results of the prospective observational cohort study, GO-PRACTICE
Full Papers; Authors: P. Goupille, P. Bertin, F. Tubach, E. Lespessailles, N. Harid, S. Sequeira, J.-M. Fayette, B. Fautrel, R.-M. Flipo
- 15 October 2020
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 47 (12) , 1844-1846
Axial Spondyloarthritis Disease Activity Cutoffs at Golimumab Initiation in the French GO-PRACTICE Study: Parallels With the German GO-NICE Study
In the German GO-NICE study, the effectiveness of the anti-TNF-α golimumab (GOL) was assessed in 501 patients with AS over 2 years, using the BASDAI8. A posthoc analysis of 244 biologic-naïve patients with AS revealed that even those with baseline BASDAI as low as 2.8 responded significantly to GOL. Baseline CRP, however, had no effect on disease activity improvement9. Our objective is to supplement these findings by presenting a similar posthoc analysis from the French GO-PRACTICE study, the results of which provide further evidence to challenge the current BASDAI cutoff of 4.0 for anti-TNF-α initiation.
- 15 October 2020
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 47 (12) , 1844-1846
Axial Spondyloarthritis Disease Activity Cutoffs at Golimumab Initiation in the French GO-PRACTICE Study: Parallels With the German GO-NICE Study
In the German GO-NICE study, the effectiveness of the anti-TNF-α golimumab (GOL) was assessed in 501 patients with AS over 2 years, using the BASDAI8. A posthoc analysis of 244 biologic-naïve patients with AS revealed that even those with baseline BASDAI as low as 2.8 responded significantly to GOL. Baseline CRP, however, had no effect on disease activity improvement9. Our objective is to supplement these findings by presenting a similar posthoc analysis from the French GO-PRACTICE study, the results of which provide further evidence to challenge the current BASDAI cutoff of 4.0 for anti-TNF-α initiation.